Adamas Pharmaceuticals Inc (ADMS) : Brenner West Capital Advisors scooped up 473,762 additional shares in Adamas Pharmaceuticals Inc during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Aug 15, 2016. The investment management firm now holds a total of 1,017,000 shares of Adamas Pharmaceuticals Inc which is valued at $13,729,500.Adamas Pharmaceuticals Inc makes up approximately 1.16% of Brenner West Capital Advisors’s portfolio.
Other Hedge Funds, Including , Schwab Charles Investment Management Inc boosted its stake in ADMS in the latest quarter, The investment management firm added 7,000 additional shares and now holds a total of 27,472 shares of Adamas Pharmaceuticals Inc which is valued at $370,872. Quantbot Technologies Lp sold out all of its stake in ADMS during the most recent quarter. The investment firm sold 649 shares of ADMS which is valued $9,625. Strs Ohio sold out all of its stake in ADMS during the most recent quarter. The investment firm sold 38,800 shares of ADMS which is valued $566,480.
Adamas Pharmaceuticals Inc opened for trading at $13.74 and hit $15.12 on the upside on Thursday, eventually ending the session at $15.07, with a gain of 10.24% or 1.4 points. The heightened volatility saw the trading volume jump to 4,41,260 shares. Company has a market cap of $330 M.
Many Wall Street Analysts have commented on Adamas Pharmaceuticals Inc. Noble Financial Initiated Adamas Pharmaceuticals Inc on Jun 17, 2016 to “Buy”, Price Target of the shares are set at $25.Mizuho Upgraded Adamas Pharmaceuticals Inc on Jun 16, 2016 to ” Buy”, Price Target of the shares are set at $22.
Adamas Pharmaceuticals Inc. is a specialty pharmaceutical company focused on development and commercialization of therapeutics targeting chronic disorders of central nervous systems (CNS). It is engaged in modifying pharmacokinetic (PK) profiles of approved drugs to create therapeutics for use alone and in fixed-dose combination products. It develops its lead product ADS-5102 (amantadine hydrochloride) for a complication associated with treatment of Parkinson’s disease known as levodopa induced dyskinesia and as a treatment for one or more additional CNS indications. Its other product candidate is ADS-8704. Through a partnership with Forest Laboratories Holdings Limited its portfolio includes two drugs commercially available in the United States: Namzaric (memantine hydrochloride extended-release and donepezil hydrochloride) and Namenda XR (memantine hydrochloride) extended release and donepezil hydrochloride) and Namenda XR (memantine hydrochloride) extended release capsules.